From GlobeNewswire: 2025-05-30 17:21:00

Perspective Therapeutics, Inc. presented updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the ASCO Annual Meeting. The trial showed favorable safety profiles and no dose-limiting toxicities in 42 patients. Four of seven patients in Cohort 2 had objective responses, with seven out of nine patients free from disease progression after a year. The first patient with a confirmed response remained in response for over 10 months. The study continues to show promise as a potential treatment option for patients with progressive NETs. Perspective plans to submit longer safety follow-up data and preliminary efficacy data for presentation later this year. Perspective presented updated interim results from its Phase 1/2a study of [212Pb]VMT-α-NET, showing a favorable safety profile with no dose-limiting toxicities. Four out of seven patients in Cohort 2 had objective responses, with three confirmed responses lasting over a year. A conference call will be held on June 2, 2025, to discuss the data. The Company is developing treatments for various cancers using alpha-emitting isotope 212Pb. Neuroendocrine tumors, which have over 170,000 people living with the diagnosis in the US, are a primary focus. Perspective is striving to personalize treatment and improve patient outcomes. Perspective Therapeutics presented updated interim results from their Phase 1/2a study on [212Pb]VMT-α-NET, showing a favorable safety profile with no dose-limiting toxicities. Seven out of nine patients remained free from disease progression after one year. Four out of seven patients in Cohort 2 had objective responses. Perspective will hold a conference call on June 2, 2025. The company aims to pioneer advanced cancer treatments, including [212Pb]VMT-α-NET, to benefit patients with NETs. They plan to enhance operations to support patient demand and pursue dose escalation in clinical trials. Forward-looking statements should be considered with caution.

Read more at GlobeNewswire: Perspective Therapeutics Highlights Updated Interim Data